An interventional study of Screening thourgh examinations including bonescintigraphy in Cardiac Amyloidosis and Chest Pain, sponsored by Rigshospitalet, Denmark. Recruiting at 1 site in Denmark. Open to male participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Amyloid Neuropathies, Familial with a site in Denmark — 6 open to participants now, 7 under way, 2 of them phase 3. Amyloid Neuropathies, Familial · Denmark.
Among the 11 studies in Amyloid Neuropathies, Familial with a site in Denmark, this one is one of 2 that started in 2024, is one of 5 with no phase, and was the 9th registered.
188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.
Browse Amyloid Neuropathies, Familial studies →6 of the 11 studies in Amyloid Neuropathies, Familial with a site in Denmark are open now. Recruiting first, the newest first:
Eidos Therapeutics, a BridgeBio company · Sites in Denmark, United States, Argentina and 21 more countries
Ages 18–75
Steen Hvitfeldt Poulsen · Sites in Denmark
Ages 65+
Steen Hvitfeldt Poulsen · Sites in Denmark
Ages 65+
Alnylam Pharmaceuticals · Sites in Denmark, United States, Brazil and 9 more countries
Region Skane · Sites in Denmark, Sweden
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 65 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 300 is above the median of 54 across 90 interventional studies indexed under Amyloid Neuropathies, Familial.
Median enrollment 200 across the 9 interventional studies, 835 across the 2 observational. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 11 have an industry lead sponsor. The 6 most frequent:
Rigshospitalet, Denmark is the lead sponsor of 1,004 studies on the registry; 173 are open to participants now.
Rigshospitalet, Denmark has 1 study filed under Amyloid Neuropathies, Familial — fewer than ten, so there is no comparison to draw.
1 of the studies in Amyloid Neuropathies, Familial with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07435168Rigshospitalet, DenmarkCHEST-CA: Study of Chest Pain and Hidden Cardiac Amyloidosis | 2027-04-01 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Amyloid Neuropathies, Familial with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this observational, prospective study is to determine the prevalence of Cardiac Amyloidosis (CA) in males over the age of 65 who experience chest pain but show no signs of coronary artery disease (CAD).
Prior to inclusion, all patients will have undergone a CT coronary angiogram or an Rb-PET scan to rule out the possibility of CAD.
Participants will be subject to several examinations, including blood tests, urine samples, ECG, echocardiography, and bone scintigraphy. An endomyocardial biopsy may be conducted if necessary.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
No signs of CAD through Rb-PET and/or CT coronary arteriogram
Exclusion Criteria:
Previous history of amyloidosis
Other: Screening thourgh examinations including bonescintigraphy
Clinical examination, blood samples, echo, bone scintigraphy
Prevalence of ATTR-CA in patients experiencing chest pain
Time frame: Up to 4 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Apr 2027, 36 months after the start.
Of 30 interventional studies with no phase under Amyloid Neuropathies, Familial, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 67. This study's planned 36 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyloid Neuropathies, Familial →